[HTML][HTML] Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

PH Deprez, LMG Moons, D OʼToole, R Gincul… - …, 2022 - thieme-connect.com
1 ESGE recommends endoscopic ultrasonography (EUS) as the best tool to characterize
subepithelial lesion (SEL) features (size, location, originating layer, echogenicity, shape) …

Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma

RS Traweek, BM Cope, CL Roland, EZ Keung… - Frontiers in …, 2022 - frontiersin.org
Dedifferentiated liposarcoma (DDLPS) is an aggressive adipogenic cancer with poor
prognosis. DDLPS tumors are only modestly sensitive to chemotherapy and radiation, and …

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

MM Gounder, NP Agaram, SE Trabucco… - Nature …, 2022 - nature.com
There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

Retroperitoneal sarcoma care in 2021

E Schmitz, C Nessim - Cancers, 2022 - mdpi.com
Simple Summary Soft-tissue sarcomas are exceedingly rare, accounting for< 1% of all adult
malignancies. Sarcomatous tumors are located within the retroperitoneum in< 10% of cases …

Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients

G Crisafulli, A Sartore-Bianchi, L Lazzari, F Pietrantonio… - Cancer Discovery, 2022 - AACR
The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient
and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond …

METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma

HB Li, G Huang, J Tu, DM Lv, QL Jin, JK Chen… - …, 2022 - thelancet.com
Background Osteosarcoma (OS) is the most common primary malignant bone tumor in
adolescents. The molecular mechanism behind OS progression and metastasis remains …

Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics

CY Lee, M The, C Meng, FP Bayer… - Molecular Systems …, 2024 - embopress.org
Kinase inhibitors (KIs) are important cancer drugs but often feature polypharmacology that is
molecularly not understood. This disconnect is particularly apparent in cancer entities such …

Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma

J Liu, T Gao, Z Tan, S Li, J Xu, C Bai, R Xue, L Xie… - Clinical Cancer …, 2022 - AACR
Purpose: To explore the efficacy and safety of TQB2450 combined with anlotinib in patients
with locally advanced or metastatic soft-tissue sarcoma (LA/M STS). Patients and Methods …

[HTML][HTML] Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

JY Blay, M von Mehren, RL Jones, J Martin-Broto… - ESMO open, 2023 - Elsevier
Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft
tissue sarcomas. Although it can occur at any age, it typically affects younger adults and …

Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features

FH Wang, HL Zheng, JT Li, P Li, CH Zheng… - La radiologia …, 2022 - Springer
Objective Development and validation of a radiomics nomogram for predicting recurrence
and adjuvant therapy benefit populations in high/intermediate-risk gastrointestinal stromal …